Effects of Cardioprotective Tactics on the Myocardial Perfusion and Contractile Function of the Left Ventricular Myocardium in Cancer Patients with Evidence of Doxorubicin-Induced Cardiotoxicity

Aim      To study the effect of cardioprotective tactics on parameters of left ventricular myocardial perfusion and contractility as per data from single-photon emission computed tomography in oncological patients with signs of anthracycline-induced cardiotoxicity.

Material and methods  The study included patients with oncological diseases (n=61) referred to polychemotherapy (PCT). For patients with signs of anthracycline-induced cardiotoxicity, a cardioprotective tactics was used, which included changing the PCT schedule and administering beta-blockers and angiotensin-converting enzyme inhibitors. For all patients at baseline, after the first four PCH courses, after initiation of the cardioprotective tactics and the next four PTC courses, the level of N-terminal pro-brain natriuretic peptide was measured and echocardiography and perfusion single-photon emission computed tomography were performed with assessment of left ventricular (LV) perfusion heterogeneity, systolic and diastolic function.

Results Following four PTC courses, signs of cardiotoxicity were detected in 13 (21.3 %) patients. On the background of the cardioprotective tactics, a further decrease in LV ejection fraction (EF) by –9±2 % (p<0.01) was observed in 4 (30.8 %) patients. In 9 (69.2 %) patients, LV EF increased by 4±2 % (p<0.01). Standard indexes of LV myocardial perfusion did not significantly change. In 7 patients, the cardioprotective tactics was associated with reduced severity of myocardial perfusion disorder, LV∆σТ = –1.37±1.29 (p<0.05), and in 4 patients, with reduced heterogeneity of myocardial perfusion, LV∆σН = –1.20±0.70 (p<0.05).

Conclusion      The cardioprotective tactics prevents both further disorder of perfusion and decreases in parameters of left ventricular myocardial contractility in patients with anthracycline-induced cardiotoxicity.

1. Valcovici M, Andrica F, Serban C, Dragan S. Cardiotoxicity of anthracycline therapy: current perspectives. Archives of Medical Science. 2016;12(2):428–35. DOI: 10.5114/aoms.2016.59270

2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 2003;97(11):2869–79. DOI: 10.1002/cncr.11407

3. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology. 2020;31(2):171–90. DOI: 10.1016/j.annonc.2019.10.023

4. Ansheles A.A., Sergienko I.V., Sergienko V.B. Method of myocardial perfusion initial disturbances and non-uniformity quantitative assessment according to single photon emission computed tomography data. Patent RU 2601098 С1. Application: 2015122258/14 from 2015.06.10. Av. at: https://yandex.ru/patents/doc/RU2601098C1_20161027.2015.

5. Ansheles A.A., Prus Yu.A., Sergienko I.V. Early detection of myocardial perfusion impairments in oncological patients undergoing polychemotherapy. Atherosclerosis and Dyslipidemias. 2020;3(40):60– 8. DOI: 10.34687/2219-8202.JAD.2020.03.0007

6. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981–8. DOI: 10.1161/CIRCULATIONAHA.114.013777

7. Cai F, Luis M, Lin X, Wang M, Cai L, Cen C et al. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment (Review). Molecular and Clinical Oncology. 2019;11(1):15–23. DOI: 10.3892/mco.2019.1854

8. Armenian SH, Ehrhardt MJ. Optimizing Cardiovascular Care in Children With Acute Myeloid Leukemia to Improve Cancer-Related Outcomes. Journal of Clinical Oncology. 2019;37(1):1–6. DOI: 10.1200/JCO.18.01421

9. Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ et al. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404. Journal of Clinical Oncology. 2016;34(8):854–62. DOI: 10.1200/JCO.2015.60.8851

10. Ganatra S, Nohria A, Shah S, Groarke JD, Sharma A, Venesy D et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology. 2019;5(1):1. DOI: 10.1186/s40959-019-0036-7

11. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. The Cochrane Database of Systematic Reviews. 2011;6:CD003917. DOI: 10.1002/14651858.CD003917.pub4

12. Lipshultz SE, Herman EH. Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovascular Research. 2018;114(2):205–9. DOI: 10.1093/cvr/cvx246

13. Renu K, Abilash VG, Tirupathi PB, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy – An update. European Journal of Pharmacology. 2018;818:241–53. DOI: 10.1016/j.ejphar.2017.10.043

14. Bansal N, Adams MJ, Ganatra S, Colan SD, Aggarwal S, Steiner R et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardio-Oncology (London, England). 2019;5:18. DOI: 10.1186/s40959-019-0054-5

15. Murabito A, Hirsch E, Ghigo A. Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer? Frontiers in Cardiovascular Medicine. 2020;7:35. DOI: 10.3389/fcvm.2020.00035

16. Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S et al. Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure. The Journal of Heart and Lung Transplantation. 2005;24(12):2196–201. DOI: 10.1016/j.healun.2004.12.108